Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Ltd has requested a trading halt for its securities pending an announcement regarding the outcome of a futility analysis for its Phase III trial of Eftilagimod Alfa. The halt is intended to prevent trading on an uninformed basis until the announcement is made. The trading halt will remain in effect until the earlier of the announcement or the commencement of normal trading on a specified date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-69
Earlier from Immutep
- Half Yearly Report and Accounts
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Quarterly Activities Report and Appendix 4C
Later from Immutep
- Suspension from Quotation
- Reinstatement to Quotation
- TACTI-004 to be discontinued following futility analysis
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- Update on Phase I Study of IMP761 for Autoimmune Diseases
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep